NYSE:ZBHZimmer Biomet Stock Price, Forecast & News

$131.25

+0.88 (+0.68 %)

(As of 06/4/2020 12:47 PM ET)

Add

Compare

Today's Range

$129.18

Now: $131.25▼

$132.05

50-Day Range

$109.26

MA: $118.61▼

$128.48

52-Week Range

$74.37

Now: $131.25▼

$161.11

Volume19,840 shs

Average Volume1.38 million shs

Market Capitalization$27.09 billion

P/E Ratio72.51

Dividend Yield0.75%

Beta1.32

Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and office based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Zimmer Biomet has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 20 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $145.67, Zimmer Biomet has a potential upside of 11.6% from its current price of $130.52.
Amount of Analyst Coverage
Zimmer Biomet has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.8 Community Rank

Outperform Votes
Zimmer Biomet has received 790 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Zimmer Biomet has received 623 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Zimmer Biomet has received 55.91% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote “Outperform” if you believe ZBH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.

3.3 Dividend Strength

Dividend Leadership
Zimmer Biomet is a leading dividend payer. It pays a dividend yield of 0.75%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Zimmer Biomet does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Zimmer Biomet is 12.20 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Zimmer Biomet will have a dividend payout ratio of 12.36 % next year. This indicates that Zimmer Biomet will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zimmer Biomet insiders have sold 232.87% more of their company's stock than they have bought. Specifically, they have bought $113,000.00 in company stock and sold $376,140.00 in company stock.
Percentage Held by Insiders
Only 0.44% of the stock of Zimmer Biomet is held by insiders.
Percentage Held by Institutions
88.11% of the stock of Zimmer Biomet is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Zimmer Biomet are expected to grow by 103.94% in the coming year, from $3.81 to $7.77 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zimmer Biomet is 72.11, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.27.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zimmer Biomet is 72.11, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.78.
Price to Earnings Growth Ratio
Zimmer Biomet has a PEG Ratio of 4.92. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Zimmer Biomet has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.49 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Surgical appliances & supplies

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:ZBH

Previous SymbolNYSE:ZMH

CUSIPN/A

CIK1136869

Webwww.zimmerbiomet.com

Phone574-267-6131

Debt

Debt-to-Equity Ratio0.65

Current Ratio1.69

Quick Ratio1.03

Price-To-Earnings

Trailing P/E Ratio72.51

Forward P/E Ratio34.45

P/E Growth4.92

Sales & Book Value

Annual Sales$7.98 billion

Price / Sales3.39

Cash Flow$13.42 per share

Price / Cash Flow9.78

Book Value$60.25 per share

Price / Book2.18

Profitability

EPS (Most Recent Fiscal Year)$7.87

Net Income$1.13 billion

Net Margins4.84%

Return on Equity13.29%

Return on Assets6.47%

Miscellaneous

Employees19,900

Outstanding Shares206,400,000

Market Cap$27.09 billion

Next Earnings Date7/24/2020 (Estimated)

OptionableOptionable

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

How has Zimmer Biomet's stock been impacted by COVID-19 (Coronavirus)?

Zimmer Biomet's stock was trading at $111.19 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ZBH shares have increased by 17.4% and is now trading at $130.52. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zimmer Biomet?

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 5 hold ratings, 20 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zimmer Biomet.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release its next quarterly earnings announcement on Friday, July 24th 2020. View our earnings forecast for Zimmer Biomet.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings Inc (NYSE:ZBH) released its quarterly earnings data on Monday, May, 11th. The medical equipment provider reported $1.70 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.53 by $0.17. The medical equipment provider had revenue of $1.78 billion for the quarter, compared to analysts' expectations of $1.79 billion. Zimmer Biomet had a return on equity of 13.29% and a net margin of 4.84%. The company's revenue for the quarter was down 9.7% on a year-over-year basis. During the same period last year, the business posted $1.87 EPS. View Zimmer Biomet's earnings history.

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet announced a quarterly dividend on Tuesday, March 10th. Shareholders of record on Friday, March 27th will be given a dividend of $0.24 per share on Thursday, April 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.74%. The ex-dividend date is Thursday, March 26th. View Zimmer Biomet's dividend history.

What guidance has Zimmer Biomet issued on next quarter's earnings?

Zimmer Biomet updated its first quarter 2020 After-Hours earnings guidance on Monday, April, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.768-1.788 billion, compared to the consensus revenue estimate of $1.93 billion.

What price target have analysts set for ZBH?

27 Wall Street analysts have issued 1-year price objectives for Zimmer Biomet's shares. Their forecasts range from $115.00 to $177.00. On average, they expect Zimmer Biomet's stock price to reach $145.67 in the next year. This suggests a possible upside of 11.6% from the stock's current price. View analysts' price targets for Zimmer Biomet.

Has Zimmer Biomet been receiving favorable news coverage?

News coverage about ZBH stock has been trending very negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zimmer Biomet earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutZimmer Biomet.

Who are some of Zimmer Biomet's key competitors?

Some companies that are related to Zimmer Biomet include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), COLOPLAST A/S/ADR (CLPBY), Align Technology (ALGN), Smith & Nephew (SNN), Steris (STE), DEMANT A S/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Wound Management Technologies (WNDM), Avanos Medical (AVNS), Inogen (INGN), Establishment Labs (ESTA), Invacare (IVC) and RTI Surgical (RTIX). View all competitors.

What other stocks do shareholders of Zimmer Biomet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zimmer Biomet investors own include Walt Disney (DIS), AT&T (T), Cisco Systems (CSCO), Intel (INTC), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and Verizon Communications (VZ).

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the following people:

Mr. Bryan C. Hanson, Pres, CEO & Director (Age 52)
Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 55)
Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 47)
Mr. Sang Yi, Pres of Asia Pacific (Age 57)
Mr. Ivan Tornos, Group Pres of Orthopedics (Age 43)

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.39%), Massachusetts Financial Services Co. MA (5.15%), State Street Corp (4.14%), JPMorgan Chase & Co. (4.01%), Invesco Ltd. (3.96%) and Capital Research Global Investors (3.80%). Company insiders that own Zimmer Biomet stock include Arthur J Higgins, Aure Bruneau, Betsy J Bernard, Bryan C Hanson, Chad F Phipps, Didier Deltort, Michael J Farrell, Michael W Michelson, Sang Yi, Syed A Jafry and Tony W Collins. View institutional ownership trends for Zimmer Biomet.

Which institutional investors are selling Zimmer Biomet stock?

ZBH stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, BlackRock Inc., The Manufacturers Life Insurance Company , Alliancebernstein L.P., Invesco Ltd., Nuveen Asset Management LLC, Balyasny Asset Management LLC, and JPMorgan Chase & Co.. Company insiders that have sold Zimmer Biomet company stock in the last year include Aure Bruneau, Chad F Phipps, Didier Deltort, and Sang Yi. View insider buying and selling activity for Zimmer Biomet.

Which institutional investors are buying Zimmer Biomet stock?

ZBH stock was bought by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Johnson Investment Counsel Inc., Primecap Management Co. CA, Franklin Resources Inc., AXA, Thrivent Financial for Lutherans, Swiss National Bank, and Reinhart Partners Inc.. Company insiders that have bought Zimmer Biomet stock in the last two years include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Michael J Farrell, Michael W Michelson, and Syed A Jafry. View insider buying and selling activity for Zimmer Biomet.

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $130.52.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $26.94 billion and generates $7.98 billion in revenue each year. The medical equipment provider earns $1.13 billion in net income (profit) each year or $7.87 on an earnings per share basis. Zimmer Biomet employs 19,900 workers across the globe.

What is Zimmer Biomet's official website?

The official website for Zimmer Biomet is www.zimmerbiomet.com.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff